ReviewBiochimica et biophysica acta. Reviews on cancer2026
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer.
Review in Biochimica et biophysica acta. Reviews on cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
High-grade serous ovarian cancer (HGSOC) is often programmed to rely heavily on mitochondrial metabolism, an adaptation that is linked to disease progression as well as resistance to standard treatments and immunotherapies. As such, mitochondrial metabolism has emerged as a promising therapeutic vulnerability to overcome resistance and selectively eliminate HGSOC cells. Several agents targeting mitochondrial metabolism are currently in or advancing toward clinical trials for various cancers. Additionally, multiple FDA-approved drugs have been repurposed to target this metabolism, and recent studies demonstrate their potential use in HGSOC therapy. This review describes the molecular mechanisms underlying mitochondrial metabolic rewiring in HGSOC and outlines the role of this rewiring in disease progression, immune evasion, and treatment resistance. In addition, we discuss current challenges and potential strategies to exploit this metabolic remodeling for more effective treatment of HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.